in

Silicon Valley's next risky self-optimization craze is unproven peptides




For many of these uses, the scientific backing is far weaker than that for GLP-1 drugs. Yet many users extrapolate from the proven success of GLP-1s to dozens of untested, unrelated peptides – often without randomized, placebo-controlled trials or independent, peer-reviewed publications. This dynamic blurs the line between legitimate pharmacology…

Read Entire Article



Source link

Nvidia GeForce Now expected to gain official Linux support as early as this week

This open-source tool uses AI to translate Japanese retro games on the fly